Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia

详细信息    查看全文

• 作者：Vicent Guillem^a ; Paula Amat^a ; Francisco Cervantes^b ; Alberto Alvarez-Larrá ; n^c ; Jose Cervera^d ; Margherita Maffioli^b ; Beatriz Bellosillo^e ; Marí ; a Collado^a ; Isabel Marugá ; n^a ; Francisco Martí ; nez-Ruiz^f ; Juan-Carlos Herná ; ndez-Boluda^a ; ^{hernandez_jca@gva.es}
• 关键词：Chronic myeloid leukemia ; Genetic polymorphisms ; Phosphatases ; Suppressors of cytokine signaling ; Imatinib
• 刊名：Leukemia Research
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：36
• 期：2
• 页码：174-181
• 全文大小：336 K

文摘

The function of the natural modulators of BCR-ABL-induced signaling pathways could influence the results to imatinib treatment. We assessed the association between single nucleotide polymorphisms (SNPs) on genes of the phosphatase family and the suppressors of cytokine signaling and the response to imatinib in 105 patients newly diagnosed with chronic-phase CML. SNPs in SOCS1 (rs243327) and PTPN22 (rs2476601) genes correlated with the risk of primary resistance to imatinib. A high-risk Sokal score, the T allele in PTPN22 SNP, and each copy of the C allele in SOCS1 SNP were adverse prognostic factors for failure-free survival (FFS). Based on such parameters, three risk groups were identified, with the 5-year FFS for each group being 95 % , 75 % , and 50 % , respectively (P < 0.001). A simple predictive model including Sokal score and genotype of SOCS1 and PTPN22 SNPs may be useful in the selection of the initial treatment in CML.